CHP 601--TALL 104 CELLS IN CHILDREN WITH ADVANCED RECURRENT REFRACTORY CANCER

7名患者参加了本试验。所有七个人都有广泛的 治疗和非常免疫抑制。当没有副作用时， 前3例患者，方案修改如下： 1)允许每例患者1次剂量递增; 2)前8次给药间隔从28天缩短至14天 周; 3)在住院的前48小时内，如果没有副作用发生， 继续在门诊部; 4)合格性扩大至包括诊断为恶性肿瘤的患者 在21岁之前 4例患者完成治疗，均出现肿瘤进展。三个是 正在接受治疗NK活性的显著变化， 一些病人。值得注意的是，与犬患者相比， 在这项试验中，没有人产生TALL-104的抗体。

Seven patients have entered this trial. All seven have had extensive therapy and are very immunosuppressed. When no side effects were noted in the first 3 patients, the protocol was modified as follows: 1) allow 1 dose escalation per patient; 2) shorten interval between doses from 28 days to 14 days for first 8 weeks; 3) administer the first 48 hours in hospital, and if no side effects occur continue in the outpatient department; 4) eligibility expanded to include patients whose malignancy was diagnosed before age 21. Four patients completed therapy and all had tumor progression. Three are undergoing treatment now. Significant changes in NK activity were noted in some patients. Remarkably, in contrast to canine patients in a comparable trial, no human has made antibody to TALL-104.